Introduction
Mycophenolic acid (MPA), the active moiety of mycophenolate mofetil (MMF), is a non-nephrotoxic, cornerstone immunosuppressant in kidney transplantation. MPA undergoes extensive entero-hepatic recirculation initiated by almost complete hepatic glucuronidation into the inactive MPA-7-O-glucuronide (MPAG) ( ) and active biliary excretion of this metabolite by the Multidrug 1
Resistance-associated Protein-2 (MRP2) ( ). It is thought that, after MPAG hydrolysis by intestinal flora, the amount of MPA reabsorbed 2 could represent 10 to 60 of total MPA exposure ( ). Consequently, inhibitors of MPA entero-hepatic cycling (including cyclosporine) % 1 affect MPA levels ( , ). Although significant associations between polymorphisms in enzymes involved in MPA glucuronidation and 3 4
MMF pharmacokinetics were described, results differed depending on the post-transplantation period and comedications and could not always be replicated (see ). The hepatic uptake of MPA and/or MPAG being a prerequisite for MPA entero-hepatic supplementary Table 1 recirculation, it could contribute to the pharmacokinetic variability and drug-drug interactions of MPA-based formulations. There has been only one indirect hint about the implication of the Organic Anion Transporting Polypeptides (OATPs) localized to the sinusoidal membrane of the hepatocytes in the disposition of MMF. Specifically, Miura et al. reported an association between and OATP1B3 polymorphisms and MPAG and MPA pharmacokinetics in Japanese renal transplants ( , ). OATP1B1 5 6 This study aimed to determine whether MPA and MPAG are substrates of the main OATP expressed in hepatocytes (OATP1B1 and 1B3) or enterocytes (OATP1A2) and the effect of genetic variations in competent transporters on MPA pharmacokinetics in renal transplant recipients receiving MMF combined with different other immunosuppressants, taking into account other SNPs previously reported to affect MPA pharmacokinetics.
Identification and frequency distribution of patient genotypes
Our clinical pharmacogenetic investigation was primarily based on our aforementioned results and thus aimed to assess the in-vitro effect of and polymorphisms on MMF pharmacokinetics. In addition, patients were genotyped for polymorphisms in SLCO1B3 SLCO1B1
and previously reported to significantly affect MPA pharmacokinetics. UGT1A9, UGT1A8 ABCC2, SNPs to be investigated in genes were selected from the literature and from the SOPHIE (Study of Pharmacogenetics in SLCO Ethnically Diverse Populations) database ( ). Two frequent coding, non-synonymous SNPs in http://pharmacogenetics.ucsf.edu/index.html complete linkage disequilibrium were reported in (T334G, G699A) ( ). In the Caucasian group of the SOPHIE cohort one SLCO1B3 7
additional common non-synonymous SNP was found in (G767C) with allele frequency of 0.18, and three in SLCO1B3 SLCO1B1
(A388G, C463A and T521C) with allelic frequencies of 0.44, 0.16 and 0.17, respectively.
No linkage disequilibrium was observed between the T334G and G767C SNPs. In contrast, for , the A388G SLCO1B3 SLCO1B1
SNP showed a strong linkage disequilibrium with the C463A (D l; r 0.21) and the T521C (D 0.79; r 0.17) SNPs, while there was no
linkage between the C463A and the T521C SNPs. This lead to six haplotypes: A-C-T (0.53), G-C-C (known as SLCO1B1 SLCO1B1 15; * 0.15), G-C-T (0.14), G-A-T (0.13), A-C-C (0.021), and G-A-C (0.004). with sirolimus or tacrolimus, the two sub-groups of patients were combined for the pharmacogenetic study. In contrast, patients co-treated with cyclosporine were studied independently as they received significantly higher doses of MMF (1890 679mg) and had lower MPA 
SLCO genotypes and MMF pharmacokinetics
In patients receiving MMF in combination with cyclosporine (n 115), no significant association between or genotypes = SLCO1B3 1B1
or haplotypes and MPA dn-AUC was found ( ).
0-12h Table 1 In 70 patients co-treated with sirolimus or tacrolimus, MPAG dn-AUC showed a trend to a gradual decrease with the number of 0-9h T334 alleles ( ). Although not significant, important differences in MPAG dose-normalized levels were observed at all SLCO1B3 Table 2 the sampling time points ( ). The metabolic ratio of MPAG to MPA showed a very significant decrease in carriers of the In these patients, MPA dose-normalized exposure was significantly different depending on T334G genotype ( ): the SLCO1B3 Table 2 T334 allele resulted in significantly higher MPA dose-normalized levels at every concentration-time points, except T (p SLCO1B3 
334GG genotype (n 48). There was no difference in T ( ). MPA AUC was studied as a surrogate for enterohepatic cycling: Table 2 4-9h patients heterozygous or homozygous for the T334 allele (n 22) had significantly higher MPA dn-AUC than other patients SLCO1B 3 (n 48; p 0.0027). However, they also had higher dn-AUC (p 0.0008), resulting in unchanged AUC /AUC ratio (p 0.4945). 
UGT and ABCC2 genotypes and MMF pharmacokinetics
In patients co-treated with cyclosporine, no influence of and polymorphisms was observed on MPA dn-AUC ( UGT1A8 1A9 0-12h Table  ) . There was a trend towards an association between the C-24T SNP and MPA dn-AUC , however, without apparent 1 ABCC2
0-12h additivity: heterozygotes for this SNP showed higher MPA dn-AUC than homozygotes for the reference or the variant genotype.
0-12h
No significant association of or genotypes with MPAG exposure was found in patients co-treated with ABCC2, UGT1A8 UGT1A9 tacrolimus or sirolimus ( ). Regarding MPA pharmacokinetics, a trend to lower MPA dn-C was found in two patients Table 3 max heterozygous for the T98C genotype as compared to patients of the reference genotype (p 0.0344; NS after Bonferroni UGT1A9 = correction). However, no association between this polymorphism and other MPA (or MPAG) exposure indices or with MPAG/MPA ratio was found ( ). Table 3 The C518G SNP tended to be associated with MPA dn-C (p 0.0130), C (p 0.0368) and dn-AUC (p 0.0171; UGT1A8 0 = max = 0-12h = Table 3 ) but not with MPAG exposure indices ( ) or MPAG/MPA ratio. Finally, patients homozygous for the C-440T variant Table 3 UGT1A9 genotype (n 4) had significantly lower MPA T than patients heterozygous or homozygous for the reference allele, but similar MPA or = max MPAG exposure indices.
Transport activity of OATP1B3 reference and variant proteins
The effect of the variant found to be associated with MPA clinical pharmacokinetics was investigated SLCO1B3 in-vitro.
The uptake of MPAG into cells expressing the OATP1B3 variant protein (i.e., 334G-699A haplotype) was markedly lower than in cells expressing the reference sequence. 
Discussion
This study provides direct evidence that MPAG is a substrate of the liver-specific uptake transporter OATP1B3 and that the pharmacokinetics of MPA is significantly influenced by the common T334G polymorphism of this gene in renal transplant SLCO1B3 patients receiving MMF in a cyclosporine-free immunosuppressive regimen. Reduced transport of MPAG was observed in cells expressing this particular OATP1B3 variant, which is consistent with the trend towards a gene-dose decrease in MPAG exposure with the number of variant alleles observed in these patients. We found a significant decrease in MPA dn-C and dn-AUC in carriers of the 334G allele. Based on our findings and on the change in MPAG exposure in transplant patients, we suggest that this is secondary to reduced in-vitro MPAG hepatic uptake, hence reduced re-absorption of MPA via the entero-hepatic cycling.
Entero-hepatic cycling is indeed a major feature of MPA pharmacokinetics and its contribution to MPA exposure is well-known.
MPAG is extensively produced in the liver, partly excreted into the bile and substantially hydrolysed to MPA in the small intestine, leading to MPA re-absorption estimated to contribute 10 to 60 to total MPA exposure ( ). It is generally thought that MPAG biliary % 1 excretion occurs just after its production in the liver. Here we suggest that, additionally, the active transport of circulating MPAG into hepatocytes substantially contributes to MPA enterohepatic cycling and then in MPA systemic exposure. Indeed, MPAG plasma concentrations are by far higher than those of MPA and this study strongly suggests that MPAG is actively taken up by the hepatocyte.
The trend towards higher MPAG plasma levels in patients carrying the G-allele is consistent with our findings and SLCO1B3 in-vitro supports the hypothesis that reduced OATP1B3 activity would decrease MPAG hepatic uptake. Nonetheless, the change in MPAG levels was not significant, maybe because renal elimination is the main disposition pathway for this metabolite. Thus, despite reducing MPA re-circulation, the decrease in MPAG biliary excretion might have a limited effect on MPAG overall elimination.
We did not observe any association between this SNP and MPA exposure in 115 patients co-treated with cyclosporine, which might be due to the inhibitory effect of cyclosporine on MPA biliary excretion. Inhibition of MRP2 by cyclosporine will indeed reduce MPA recirculation, whatever the activity of OATP1B3 is. Looking at the means SD in the three genotype groups ( ) as well as to the p ± Table 1 value obtained, it seems that the number of patients in this comedication subgroup was sufficient to exclude any clinically relevant influence of this particular SNP on MPA exposure in patients receiving cyclosporine. In contrast, increasing the number of patients cotreated with tacrolimus or sirolimus might have allowed us to investigate a potential additive gene-dose effect.
Human OATP1B3 is mainly expressed in hepatocytes where it mediates, together with OATP1B1, the uptake of a number of drugs or endogenous compounds from blood to hepatocytes ( ). In this study, we showed that cell expression of either transporter resulted in the 10 facilitated uptake of the main metabolite of MPA (MPAG). However, OATP1B1 activity with respect to MPAG was relatively modest as compared to that of OATP1B3, suggesting limited implication of OATP1B1 in MPAG uptake as compared to OATP1B3. The in-vivo finding that none of the OATP1B1 polymorphisms or haplotypes tested in this study was significantly and markedly associated with MPA or MPAG pharmacokinetics supports this hypothesis.
We did not observe any difference between HEK293T native and OATP-expressing cells regarding the uptake of the parent drug (MPA). We cannot totally exclude that MPA is a substrate of OATP. Indeed, passive diffusion (or transport via some unknown transporter in HEK) apparently plays a much higher role in MPA than MPAG cellular transport, with a net uptake rate approximately 3-fold higher for MPA than MPAG in HEK293T native cells (0.021 vs 0.008 pmol/mg/min). This may mask the active transport of the drug (if any) in our cellular model.
OATP1A2 is highly expressed in the intestine, the kidney, in cholangiocytes and at the blood-brain barrier ( , ) where it is 10 11 supposed to play an important role in drug absorption and drug-drug interactions ( ). We observed no difference between native and 11 OATP1A2-expressing HEK293T cells regarding MPA or MPAG uptake, suggesting that these compounds are not substrates of OATP1A2.
The first study investigating the functional consequences of polymorphisms showed in stably transfected MDCKII and SLCO1B3 HEK293 cells that variant OATP1B3 proteins resulting from either of the two coding non-synonymous SNPs T334G (S122A) and G699A (M233I) had similar basolateral membrane localization with the reference protein ( ). They did not find differences in uptake activities 12 between these proteins using several model substrates (Estrone-3-sulfate, bromosulfophthalein and 17--glucuronosyl estradiol). However, β the authors did not investigate the consequence of the combined amino acid substitutions resulting from these two SNPs (in complete linkage disequilibrium). Hamada et al. found that COS-7 cells transfected with the variant haplotype (334G-699A) had a SLCO1B3 significantly reduced ability to uptake testosterone as compared to cells transfected with the reference gene or a sequence SLCO1B3 containing either the 334G or the 699A SNP ( ). In the present study, our plasmid integrated simultaneously the two SNPs and 7 SLCO1B3 we obtained results in line with those of Hamada et al, with a decreased uptake of MPAG in cells transfected with the 334G-699A variant as compared to the reference sequence. Our clinical results are compatible with decreased activity of the OATP1B3 variant protein but surprisingly different from those recently published for the same drug in Japanese patients. Miura el al. described higher dn-AUC [6] [7] [8] [9] [10] [11] [12] (regarded a marker of MPA recirculation) in patients carrying the 334GG (or 699AA) genotype as compared to carriers of the 334TT genotype ( ). Based on this pharmacokinetic observation, the authors proposed that MPA uptake into hepatocytes and excretion into bile 6 might be increased in patients with 334GG genotype. This is in contradiction with previous ( ) and the present SLCO1B3 12 in-vitro evidence that the 334G allele reduces OATP1B3 activity. Also, the present results do not support this hypothesis as MPA is not a substrate of OATP1B3 and yet we found a lower dose-normalized MPA exposure in carriers of the 334GG genotype. It should be noted in-vitro, that Miura et al. recently reported, in accordance with our hypothesis, that patients homozygous for the 334G-699A allele had SLCO1B3 significantly higher MPAG dn-AUC than patients heterozygous or homozygous for the reference allele ( ).
0-12 5
We observed an important decrease of MPA exposure in patients receiving MMF combined with cyclosporine as compared to tacrolimus or sirolimus. This difference is well-known and is thought to result from the inhibitory effect of cyclosporine on MPAG biliary excretion. The mechanisms presumably involved in this drug-drug interaction and in the pharmacogenetic association we observed are very close. It is even tempting to hypothesise that the inhibitory effect of cyclosporine might not only concern MRP2 (as generally admitted) but also OATP1B3. Indeed, studies showed that cyclosporine is a potent inhibitor of OATP1B1 and OATP1B3 ( ). in-vitro 13
This inhibitory effect was associated with drug-drug interactions of clinical relevance, in particular with statins ( , ). 14 15
Most of the pharmacogenetic studies performed regarding MMF focused on UGT enzymes or MRP2 but weak associations were mainly reported (see ).
In the present study, we tested the effect of SNPs previously associated with MPA supplementary Table 1 pharmacokinetics using stringent criteria for statistical analysis (i.e., Bonferroni correction): none of the SNPs evaluated significantly 5 13 influenced MPA pharmacokinetics, whatever the comedication. It is possible that this absence of effect, in particular for UGT1A9 SNPs previously associated with a decreased enzyme activity or expression ( , ) is related to differences in the post-transplantation in-vitro 16 17 periods at which patients were studied. Association between the C-2152T, T98C or UGT1A8 C518G SNPs were indeed UGT1A9 observed in patients studied at early post-transplantation periods (<30 days) ( ), when MPA apparent clearance (CL/F) is known to 18 -20 be higher than at later time-points ( ), presumably owing to several time-dependent factors such as the renal function, albumin and 21
haemoglobin levels, decreasing cyclosporine predose levels ( ) and inductive effect of corticosteroids on UGT ( ). However, this 22 23 cannot explain the discrepancy with the significant influence of C-440T/T-331C on MPA dn-AUC found by Baldelli et al. in UGT1A9 0-12h stable renal transplants receiving a steroid-free regimen ( ). 9
Our study certainly has some limitations: in addition to those mentioned above, potential covariates such as serum albumin, previously associated with MPAG disposition in renal transplants ( ), could not be taken in account in multivariate analyses to ponder the 9 associations (or the absence of associations) found here, contrary to what van Shaik et al. recently did ( ), because they were not 20 available in our databases.
Apart from the association of genotype with MPA pharmacokinetics (of which the relevance for MMF efficacy or tolerance SLCO1B3 remains to be investigated in a larger population), our study demonstrates for the first time that OATP proteins are involved in the pharmacokinetics of MPA. It gives new hints regarding the mechanism of drug-drug interactions, in particular with cyclosporine whose known effects on MPA and MPAG plasma levels are similar to those of the mutant allele herein. SLCO1B3
In conclusion, the pharmacokinetics of MPA in stable renal transplant patients receiving a cyclosporine-free regimen is influenced by genetic polymorphisms of the hepatic uptake transporter OATP1B3, of which MPAG is a substrate. Cyclosporine might inhibit the transporter function and thus attenuate the effect of its polymorphism.
Methods Cellular assays
-pcDNA5/FRT plasmids containing the reference sequence (NM_019844) or a sequence with two nucleotide exchanges SLCO1B3 corresponding to the T334G (rs4149117) and G699A (rs7311358) polymorphisms were constructed as described in SLCO1B3 SLCO1B3
. HBSS at 37 C for 15 min. After 5 to 10 minutes, the cells were washed twice with ice-cold uptake buffer, lysed in 250 l of NaCl 0.2N (1°μ hour at 4 C) and lysates neutralized by adding 25 l of 2N HCl. MPA and MPAG were determined using a previously described validated°μ liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay ( ). Results were normalized to per-well protein content as 3 measured using the bicinchoninic acid protein assay (Pierce, Rockford, IL).
OATP1B3-mediated net uptake kinetics was studied after 10 min of incubation with MPAG, after subtracting the uptake in empty (AUC ) were calculated using validated Bayesian models. In the absence of an adequate model for MPAG, AUC were estimated 0-12h 0-9h using the linear trapezoidal rule. The plasma metabolic ratio of MPAG to MPA was estimated as the AUC ratio. There was no 0-9h 6 13 difference in renal function between patients receiving tacrolimus or sirolimus as assessed by comparing serum creatinine levels at the time of blood sampling (p 0.7659). All these trials were approved by ethic committees.
There was no statistical difference in corticosteroid dose between patients co-treated with cyclosporine and tacrolimus or sirolimus at the time of blood sampling (p>0.05).
Patients DNA was isolated from EDTA-treated blood as previously described in details ( ) and was characterized for SNPs in ' 
27
, , , and genes using validated TaqMan allelic discrimination assays on an ABI PRISM SLCO1B3 SLCO1B1 UGT1A8 UGT1A9 ABCC2 7000 Sequence Detection System (Applied Biosystems, Courtaboeuf, France).
Statistical analysis
Pairwise linkage disequilibrium between polymorphisms was evaluated by means of D and r (calculated using Thesias software (
) and patients most probable haplotypes inferred using the PHASE program ( ). Categorical variables were compared using the Fisher s 
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